Navamedic is launching Alflorex in Norway

2019-08-05 09:30:00

“We are pleased to announce that Navamedic is entering into the gastro therapeutic area through the first probiotic product with IBS as approved indication. Alflorex® for IBS is part of a strategic partnership with PrecisionBiotics Ltd., who is developing unique bacteria cultures that have been specifically researched and rigorously tested for specific indications,” says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.

Alflorex® for IBS is classified as a medical device and contains the patented bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is clinically proven to reduce symptoms of IBS, including bloating and gas, abdominal pain, diarrhoea and constipation. About 10-15% of the population have IBS symptoms affecting their quality of life. From September 2019, Alflorex® for IBS will be available in Norwegian pharmacies helping IBS sufferers to take back control of their gut health.

“Entering into the consumer health market with unique products is key to Navamedic's growth strategy. Both the consumer health gastro therapeutic area and the probiotic market is underdeveloped in the Nordics, and we aim to drive growth in this market with this unique product”, says Kathrine Gamborg Andreassen.

The 35624® bacterial strain was first launched in the US in 2007, and has since developed into a global market leader. Alflorex® is now available in Europe, already successfully launched in selected countries.